![](/img/cover-not-exists.png)
Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Three European Countries Using 28-Month Overall Survival from Checkmate 067
Hirst, A, Paly, VF, Diamantogiannis, F, Guilmet, C, Polanco, S C, Sabater, J, Chirita, OVolume:
20
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2017.08.197
Date:
October, 2017
File:
PDF, 59 KB
english, 2017